Having trouble accessing articles? Reset your cache.

Actonel risedronate regulatory update

FDA will update the labels of all bisphosphonates approved for osteoporosis to warn of the risk of atypical fractures of the thigh.

Read the full 223 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE